Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study

Detalhes bibliográficos
Autor(a) principal: Fernandes, Ana Cristina da Silva
Data de Publicação: 2022
Outros Autores: Cesar, Jorgino Júlio, Bonolo, Palmira de Fátima, Souza, Clessius Ribeiro de, Ceccato , Maria das Graças Braga
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/28662
Resumo: Objective:  To compare the impact on lipid profile (LP) in people starting antiretroviral therapy (ART) before e after the use with efavirenz (EFZ) or dolutegravir (DTG) based regimens. Methods: A prospective cohort study stratified into two groups, the people living with HIV (PLWHIV) who started either DTG or EFV. Dyslipidemia was defined by laboratory criteria in the period from September 2015 to October 2017. Parametric and non-parametric tests and matched pair tests were used, considering p <0.05 statistically significant. Results: Studied 468 individuals stratified into two groups, with (n=180) or without (n=288) records of laboratory tests at time T0 (start of treatment) or at T48 (12 months after the dispensation of antiretroviral drugs. Among these 180, 60 (33.1%) were taking DTG and 113 (62.4%) were taking EFZ. In comparisons of serum PL level (mg/dl), pre and post ART, all values showed an increase and statically significant for HDL (p<0.001). The variation of PL was analyzed, post TARV and in relation to the use of EFV and DTG. In relation to EFZ, there was an increase in the serum level of the whole PL, statically significant for HDL.  Regarding DTG, there was increase in serum level only for VLDL which was not statically significant. Conclusion: Comparing the use of DTG with EFV, EFV increased the serum level of TC and fractions, statically significant for HDL. With the use of DTG, there was an increase in serum VLDL level and decrease in HDL-C, without statistical significance.  
id UNIFEI_16424e4666bcef2ca893868d8c500a40
oai_identifier_str oai:ojs.pkp.sfu.ca:article/28662
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort studyPerfil lipídico en personas que inician la terapia antirretroviral con regímenes basados en efavirenz o dolutegravir en un centro de referencia en Brasil: un estudio de cohortePerfil lipídico em pessoas iniciando a terapia antirretroviral com regimes baseados em efavirenz ou dolutegravir em um centro de referência no Brasil: um estudo de coorteDislipidemiaTerapia Antirretroviral de Alta AtividadeInibidores de Integrase de HIVInibidores da Transcriptase Reversa.DislipidemiaTerapia Antirretroviral Altamente ActivaInhibidores de Integrasa VIHInhibidores de la Transcriptasa Inversa.DyslipidemiaAntiretroviral Therapy, Highly ActiveHIV Integrase InhibitorsReverse Transcriptase Inhibitors.Objective:  To compare the impact on lipid profile (LP) in people starting antiretroviral therapy (ART) before e after the use with efavirenz (EFZ) or dolutegravir (DTG) based regimens. Methods: A prospective cohort study stratified into two groups, the people living with HIV (PLWHIV) who started either DTG or EFV. Dyslipidemia was defined by laboratory criteria in the period from September 2015 to October 2017. Parametric and non-parametric tests and matched pair tests were used, considering p <0.05 statistically significant. Results: Studied 468 individuals stratified into two groups, with (n=180) or without (n=288) records of laboratory tests at time T0 (start of treatment) or at T48 (12 months after the dispensation of antiretroviral drugs. Among these 180, 60 (33.1%) were taking DTG and 113 (62.4%) were taking EFZ. In comparisons of serum PL level (mg/dl), pre and post ART, all values showed an increase and statically significant for HDL (p<0.001). The variation of PL was analyzed, post TARV and in relation to the use of EFV and DTG. In relation to EFZ, there was an increase in the serum level of the whole PL, statically significant for HDL.  Regarding DTG, there was increase in serum level only for VLDL which was not statically significant. Conclusion: Comparing the use of DTG with EFV, EFV increased the serum level of TC and fractions, statically significant for HDL. With the use of DTG, there was an increase in serum VLDL level and decrease in HDL-C, without statistical significance.  Objetivo: Comparar el impacto sobre el perfil lipídico (PL) en personas que inician la terapia antirretroviral (TARV) con regímenes basados antes y después del uso de efavirenz (EFZ) o dolutegravir (DTG). Métodos: Cohorte prospectiva en la que se estratificaron dos grupos, personas que viven con el VIH (PVVS) que iniciaron el esquema con DTG o EFV. La dislipidemia se definió por criterios de laboratorio en el periodo comprendido entre septiembre de 2015 y octubre de 2017. Se utilizaron pruebas paramétricas y no paramétricas y pruebas de pares emparejados, considerando p <0,05 estadísticamente significativa. Resultados: se estudiaron 468 individuos estratificados en dos grupos, con (n=180) o sin (n=288) registros de pruebas de laboratorio en el momento T0 (inicio del tratamiento) o en el T48 (12 meses después de la dispensación de los antirretrovirales. De estos 180, 60 (33,1%) estaban en DTG y 113 (62,4%) en EFZ. En las comparaciones del nivel sérico (mg/dl) de PL, antes y después de la terapia antirretroviral, todos los valores mostraron un aumento y fueron estadísticamente significativos para el HDL (p<0,001). Se analizó la variación de la PL, post TARV y en relación con el uso de EFV y DTG. En cuanto a la EFZ, se produjo un aumento del nivel sérico de todo el PL, estadísticamente significativo para el HDL.  En cuanto a la DTG, sólo se produjo un aumento del nivel sérico de VLDL que no fue estadísticamente significativo. Conclusión: Comparando el uso de DTG con EFV, EFV aumentó el nivel sérico de TC y fracciones, siendo estadísticamente significativo para HDL. Con el uso de DTG, hubo un aumento del nivel sérico de VLDL y una disminución de HDL, sin significación estadística.Objetivo: Comparar o impacto no perfil lipídico (PL) em pessoas iniciando a terapia antirretroviral (TARV) baseados pré e pós uso de efavirenz (EFZ) ou dolutegravir (DTG). Métodos:  Coorte prospectiva onde foi estratificados dois grupos, as pessoas vivendo com HIV (PVIV) que iniciaram esquema com DTG ou EFV. A dislipidemia foi definida por critérios laboratoriais no período entre setembro de 2015 a outubro de 2017. Utilizados testes paramétrico e não paramétrico e testes de pares combinados, considerando o p <0,05 estatisticamente significativo. Resultados:  estudados 468 indivíduos estratificados em dois grupos, com (n=180) ou sem (n=288) registros dos exames laboratoriais no tempo T0 (início do tratamento) ou no T48 (12 meses após a dispensação dos antirretrovirais. Entre esses 180, 60 (33,1%) estavam em uso de DTG e 113 (62,4%) em uso de EFZ. Nas comparações do nível sérico (mg/dl) do PL, pré e pós TARV, todos os valores apresentaram aumento e estaticamente significativo para o HDL (p<0,001). Foi analisado a variação do PL, pós TARV e em relação ao uso de EFV e DTG. Em relação ao EFZ, houve aumento do nível sérico de todo o PL, estaticamente significativo para o HDL.  Em relação ao DTG, houve aumento do nível sérico apenas para o VLDL que não foi estaticamente significativo. Conclusão:  comparando o uso do DTG com o EFV, o EFV aumentou o nível sérico do CT e frações, estaticamente significativa para o HDL. Com uso do DTG, houve um aumento do nível sérico de VLDL e diminuição do HDL, sem significância estatística.Research, Society and Development2022-04-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2866210.33448/rsd-v11i5.28662Research, Society and Development; Vol. 11 No. 5; e55811528662Research, Society and Development; Vol. 11 Núm. 5; e55811528662Research, Society and Development; v. 11 n. 5; e558115286622525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/28662/24846Copyright (c) 2022 Ana Cristina da Silva Fernandes; Jorgino Júlio Cesar; Palmira de Fátima Bonolo; Clessius Ribeiro de Souza; Maria das Graças Braga Ceccato https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessFernandes, Ana Cristina da Silva Cesar, Jorgino Júlio Bonolo, Palmira de Fátima Souza, Clessius Ribeiro deCeccato , Maria das Graças Braga2022-04-17T18:18:56Zoai:ojs.pkp.sfu.ca:article/28662Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:45:59.264554Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study
Perfil lipídico en personas que inician la terapia antirretroviral con regímenes basados en efavirenz o dolutegravir en un centro de referencia en Brasil: un estudio de cohorte
Perfil lipídico em pessoas iniciando a terapia antirretroviral com regimes baseados em efavirenz ou dolutegravir em um centro de referência no Brasil: um estudo de coorte
title Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study
spellingShingle Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study
Fernandes, Ana Cristina da Silva
Dislipidemia
Terapia Antirretroviral de Alta Atividade
Inibidores de Integrase de HIV
Inibidores da Transcriptase Reversa.
Dislipidemia
Terapia Antirretroviral Altamente Activa
Inhibidores de Integrasa VIH
Inhibidores de la Transcriptasa Inversa.
Dyslipidemia
Antiretroviral Therapy, Highly Active
HIV Integrase Inhibitors
Reverse Transcriptase Inhibitors.
title_short Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study
title_full Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study
title_fullStr Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study
title_full_unstemmed Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study
title_sort Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study
author Fernandes, Ana Cristina da Silva
author_facet Fernandes, Ana Cristina da Silva
Cesar, Jorgino Júlio
Bonolo, Palmira de Fátima
Souza, Clessius Ribeiro de
Ceccato , Maria das Graças Braga
author_role author
author2 Cesar, Jorgino Júlio
Bonolo, Palmira de Fátima
Souza, Clessius Ribeiro de
Ceccato , Maria das Graças Braga
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Fernandes, Ana Cristina da Silva
Cesar, Jorgino Júlio
Bonolo, Palmira de Fátima
Souza, Clessius Ribeiro de
Ceccato , Maria das Graças Braga
dc.subject.por.fl_str_mv Dislipidemia
Terapia Antirretroviral de Alta Atividade
Inibidores de Integrase de HIV
Inibidores da Transcriptase Reversa.
Dislipidemia
Terapia Antirretroviral Altamente Activa
Inhibidores de Integrasa VIH
Inhibidores de la Transcriptasa Inversa.
Dyslipidemia
Antiretroviral Therapy, Highly Active
HIV Integrase Inhibitors
Reverse Transcriptase Inhibitors.
topic Dislipidemia
Terapia Antirretroviral de Alta Atividade
Inibidores de Integrase de HIV
Inibidores da Transcriptase Reversa.
Dislipidemia
Terapia Antirretroviral Altamente Activa
Inhibidores de Integrasa VIH
Inhibidores de la Transcriptasa Inversa.
Dyslipidemia
Antiretroviral Therapy, Highly Active
HIV Integrase Inhibitors
Reverse Transcriptase Inhibitors.
description Objective:  To compare the impact on lipid profile (LP) in people starting antiretroviral therapy (ART) before e after the use with efavirenz (EFZ) or dolutegravir (DTG) based regimens. Methods: A prospective cohort study stratified into two groups, the people living with HIV (PLWHIV) who started either DTG or EFV. Dyslipidemia was defined by laboratory criteria in the period from September 2015 to October 2017. Parametric and non-parametric tests and matched pair tests were used, considering p <0.05 statistically significant. Results: Studied 468 individuals stratified into two groups, with (n=180) or without (n=288) records of laboratory tests at time T0 (start of treatment) or at T48 (12 months after the dispensation of antiretroviral drugs. Among these 180, 60 (33.1%) were taking DTG and 113 (62.4%) were taking EFZ. In comparisons of serum PL level (mg/dl), pre and post ART, all values showed an increase and statically significant for HDL (p<0.001). The variation of PL was analyzed, post TARV and in relation to the use of EFV and DTG. In relation to EFZ, there was an increase in the serum level of the whole PL, statically significant for HDL.  Regarding DTG, there was increase in serum level only for VLDL which was not statically significant. Conclusion: Comparing the use of DTG with EFV, EFV increased the serum level of TC and fractions, statically significant for HDL. With the use of DTG, there was an increase in serum VLDL level and decrease in HDL-C, without statistical significance.  
publishDate 2022
dc.date.none.fl_str_mv 2022-04-15
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/28662
10.33448/rsd-v11i5.28662
url https://rsdjournal.org/index.php/rsd/article/view/28662
identifier_str_mv 10.33448/rsd-v11i5.28662
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/28662/24846
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 5; e55811528662
Research, Society and Development; Vol. 11 Núm. 5; e55811528662
Research, Society and Development; v. 11 n. 5; e55811528662
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052794641842176